Grant: Alliance Grants
University of Alberta
$32,000.00
AI-based Screening for Breast Cancer Treatment _x000d_
EF 2020-21
Résumé
AI-based Screening for Breast Cancer Treatment
Breast cancer is the commonest cancer affecting women. For Canada in 2014, an estimated number of 24,400 new diagnoses of breast cancer with a reported range cost of 309-454 million CAD for diagnosis and treatment. Recently, personalized medicine has increased this cost further. The goal of the proposed research is to find AI-based solutions to replace expensive molecular tests and to reduce the significant turn around time (TAT) inherent to the complexity of these molecular assays. For this project, Alberta Health Services (AHS) and DynaLIFE Medical Labs Edmonton are partnering with Dr. Nilanjan Ray and his team at Computing Science, University of Alberta.
Canadian overall healthcare quality ranking is still among the best in the world and beats the U.S. healthcare system, even though it represents 10.3% of gross domestic product (GDP) compared to 17.8% of the U.S. GDP. It is budgetarily challenging to maintain this rank. Medicine is permanently evolving, and a new paradigm includes the capacity to exploit a large amount of data through Artificial Intelligence (AI) and Machine Learning (ML) to better screen, diagnose, predict, treat and follow-up diseases. These tools can reduce costs significantly. It might be therefore critical for Canada to not only be ready to adopt these tools but to develop them. Canada has centres of excellence in the field of ML. This project is an example where these two aforementioned goals are met: 1) optimization (reduction of cost, improved TAT) of important cancer biomarkers, and 2) strengthening local ML expertise (Research, student recruitment, potential startup, and improving local economy).
Programme
Alliance Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
558274-2020
Name nom
Ray, Nilanjan
Department département
Computing Science
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
32000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
2603
Research subject group en
Robotics
Research subject group fr
Robotique
Research subject en
Computer vision
Research subject fr
Vision artificielle
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
AI-based Screening for Breast Cancer Treatment _x000d_
Keyword
NSERC
Application summary
AI-based Screening for Breast Cancer Treatment
Breast cancer is the commonest cancer affecting women. For Canada in 2014, an estimated number of 24,400 new diagnoses of breast cancer with a reported range cost of 309-454 million CAD for diagnosis and treatment. Recently, personalized medicine has increased this cost further. The goal of the proposed research is to find AI-based solutions to replace expensive molecular tests and to reduce the significant turn around time (TAT) inherent to the complexity of these molecular assays. For this project, Alberta Health Services (AHS) and DynaLIFE Medical Labs Edmonton are partnering with Dr. Nilanjan Ray and his team at Computing Science, University of Alberta.
Canadian overall healthcare quality ranking is still among the best in the world and beats the U.S. healthcare system, even though it represents 10.3% of gross domestic product (GDP) compared to 17.8% of the U.S. GDP. It is budgetarily challenging to maintain this rank. Medicine is permanently evolving, and a new paradigm includes the capacity to exploit a large amount of data through Artificial Intelligence (AI) and Machine Learning (ML) to better screen, diagnose, predict, treat and follow-up diseases. These tools can reduce costs significantly. It might be therefore critical for Canada to not only be ready to adopt these tools but to develop them. Canada has centres of excellence in the field of ML. This project is an example where these two aforementioned goals are met: 1) optimization (reduction of cost, improved TAT) of important cancer biomarkers, and 2) strengthening local ML expertise (Research, student recruitment, potential startup, and improving local economy).